Tenofit E 25 Tablet contains Emtricitabine 200 mg and Tenofovir disoproxil fumarate 25 mg, a combination of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) used in the management of HIV-1 infection. By inhibiting the viral reverse transcriptase enzyme, this combination prevents viral replication and helps achieve sustained suppression of HIV viral load.
Clinically, Tenofit E 25 Tablet is indicated for treatment-naïve and treatment-experienced patients, often as part of combination antiretroviral therapy (cART). Its efficacy in suppressing viral replication, maintaining CD4 counts, and reducing the risk of disease progression makes it essential in HIV management protocols.
The tablet formulation ensures precise dosing, reliable bioavailability, and consistent antiviral activity, supporting optimal patient adherence and therapeutic outcomes. It is suitable for hospitals, HIV specialty clinics, government ART centers, and pharmacies requiring a high-quality, PCD-ready supply of antiviral therapy.
Tenofit E 25 Tablet also contributes to overall patient health by minimizing viral resistance, reducing HIV-related complications, and improving long-term prognosis. Its potent combination of Emtricitabine and Tenofovir provides a safe, effective, and evidence-based approach to HIV therapy for both adults and adolescents under medical supervision.